FDA approve pralsetinib for advanced or metastatic RET-mutant and RET fusion-positive thyroid cancer

Accelerated approval was based on the Phase 1/2 ARROW trial, where this proto-oncogene protein C RET inhibitor provided a 60% response rate in those previously treated with cabozantinib or vandetanib. A market authorisation application has not yet been submitted to the EMA.

Source:

Biospace Inc.